Burchardt M - Search Results

1

Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells.

de la Taille A, Rubin MA, Chen MW, Vacherot F, de Medina SG, Burchardt M, Buttyan R, Chopin D. de la Taille A, et al. Among authors: burchardt m. Clin Cancer Res. 2003 May;9(5):1801-7. Clin Cancer Res. 2003. PMID: 12738737

2

Human hormone-refractory prostate cancers can harbor mutations in the O(2)-dependent degradation domain of hypoxia inducible factor-1alpha (HIF-1alpha).

Anastasiadis AG, Ghafar MA, Salomon L, Vacherot F, Benedit P, Chen MW, Shabsigh A, Burchardt M, Chopin DK, Shabsigh R, Buttyan R. Anastasiadis AG, et al. Among authors: burchardt m. J Cancer Res Clin Oncol. 2002 Jul;128(7):358-62. doi: 10.1007/s00432-002-0346-1. Epub 2002 May 16. J Cancer Res Clin Oncol. 2002. PMID: 12136249

3

The emergence of protocadherin-PC expression during the acquisition of apoptosis-resistance by prostate cancer cells.

Chen MW, Vacherot F, De La Taille A, Gil-Diez-De-Medina S, Shen R, Friedman RA, Burchardt M, Chopin DK, Buttyan R. Chen MW, et al. Among authors: burchardt m. Oncogene. 2002 Nov 7;21(51):7861-71. doi: 10.1038/sj.onc.1205991. Oncogene. 2002. PMID: 12420223

4

Apoptotic conversion: evidence for exchange of genetic information between prostate cancer cells mediated by apoptosis.

de la Taille A, Chen MW, Burchardt M, Chopin DK, Buttyan R. de la Taille A, et al. Among authors: burchardt m. Cancer Res. 1999 Nov 1;59(21):5461-3. Cancer Res. 1999. PMID: 10554018

5

Acute hypoxia increases the aggressive characteristics and survival properties of prostate cancer cells.

Ghafar MA, Anastasiadis AG, Chen MW, Burchardt M, Olsson LE, Xie H, Benson MC, Buttyan R. Ghafar MA, et al. Among authors: burchardt m. Prostate. 2003 Jan 1;54(1):58-67. doi: 10.1002/pros.10162. Prostate. 2003. PMID: 12481256

6

Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo.

Burchardt T, Burchardt M, Chen MW, Cao Y, de la Taille A, Shabsigh A, Hayek O, Dorai T, Buttyan R. Burchardt T, et al. Among authors: burchardt m. J Urol. 1999 Nov;162(5):1800-5. J Urol. 1999. PMID: 10524938 Free article.

7

Reduction of wild type p53 function confers a hormone resistant phenotype on LNCaP prostate cancer cells.

Burchardt M, Burchardt T, Shabsigh A, Ghafar M, Chen MW, Anastasiadis A, de la Taille A, Kiss A, Buttyan R. Burchardt M, et al. Among authors: burchardt t. Prostate. 2001 Sep 15;48(4):225-30. doi: 10.1002/pros.1101. Prostate. 2001. PMID: 11536301

8

Tumor hypoxia and the progression of prostate cancer.

Anastasiadis AG, Stisser BC, Ghafar MA, Burchardt M, Buttyan R. Anastasiadis AG, et al. Among authors: burchardt m. Curr Urol Rep. 2002 Jun;3(3):222-8. doi: 10.1007/s11934-002-0068-6. Curr Urol Rep. 2002. PMID: 12084192 Review.

9

What information are urologists extracting from prostate needle biopsy reports and what do they need for clinical management of prostate cancer?

Descazeaud A, Rubin MA, Allory Y, Burchardt M, Salomon L, Chopin D, Abbou C, de la Taille A. Descazeaud A, et al. Among authors: burchardt m. Eur Urol. 2005 Dec;48(6):911-5. doi: 10.1016/j.eururo.2005.07.011. Epub 2005 Aug 9. Eur Urol. 2005. PMID: 16140457

10

Herbal therapy PC-SPES: in vitro effects and evaluation of its efficacy in 69 patients with prostate cancer.

de la Taille A, Buttyan R, Hayek O, Bagiella E, Shabsigh A, Burchardt M, Burchardt T, Chopin DK, Katz AE. de la Taille A, et al. Among authors: burchardt t, burchardt m. J Urol. 2000 Oct;164(4):1229-34. doi: 10.1097/00005392-200010000-00021. J Urol. 2000. PMID: 10992371

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

177 results

Search Page

Filters